Tvardi Therapeutics
TVRD
67 hedge funds and large institutions have $8.6M invested in Tvardi Therapeutics in 2026 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 17 reducing their positions, and 12 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 17
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
0% more funds holding
Funds holding: 67 → 67 (0)
1.3% less ownership
Funds ownership: 30.11% → 28.82% (-1.3%)
29% less capital invested
Capital invested by funds: $12.1M → $8.6M (-$3.52M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$165K |
| 2 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
+$142K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$98.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$58.4K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$28.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$204K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$109K |
| 3 |
QC
Quadrature Capital
London,
United Kingdom
|
-$90.1K |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$85.4K |
| 5 |
Squarepoint
New York
|
-$74.9K |
TVRD Hedge Fund Activity: Q1 2026 in Review
67 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2026, worth a combined $8.6M — down 29% from $12.1M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new TVRD positions and 12 closed out — a net gain of 2 holders — while 20 added to existing stakes and 17 trimmed.
The largest buyer was AQR Capital Management, opening a new position worth an estimated $165K. The largest seller was Jane Street, exiting entirely with an estimated $204K sold.
- 67 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $8.6M of Tvardi Therapeutics stock for Q1 2026, down 29% quarter-over-quarter.
- 14 funds opened new Tvardi Therapeutics positions in Q1 2026 and 12 closed out, a net change of +2 holders.
- The largest Tvardi Therapeutics buyer in Q1 2026 was AQR Capital Management, an estimated $165K added.
- The largest Tvardi Therapeutics seller in Q1 2026 was Jane Street, an estimated $204K sold.
Based on aggregated 13F filings for Q1 2026.